BR112015001313A2 - composições de vacina - Google Patents
composições de vacinaInfo
- Publication number
- BR112015001313A2 BR112015001313A2 BR112015001313A BR112015001313A BR112015001313A2 BR 112015001313 A2 BR112015001313 A2 BR 112015001313A2 BR 112015001313 A BR112015001313 A BR 112015001313A BR 112015001313 A BR112015001313 A BR 112015001313A BR 112015001313 A2 BR112015001313 A2 BR 112015001313A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine compositions
- dengue
- serotype
- protecting
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
resumo patente de invenção: "composições de vacina". a presente invenção refere-se a composições de vacina do vírus da dengue sorotipo 2 que são úteis em um método de proteção de um ser humano contra a doença da dengue. a presente invenção compreende ainda um kit compreendendo uma composição de vacina do vírus da dengue sorotipo 2 e instruções de uso da dita composição em um método de proteção de um ser humano contra a doença da dengue causada por um vírus da dengue sorotipo 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305908 | 2012-07-24 | ||
EP12305911 | 2012-07-25 | ||
PCT/EP2013/065669 WO2014016362A1 (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions for prevention against dengue virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015001313A2 true BR112015001313A2 (pt) | 2017-08-01 |
Family
ID=48856641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015001313A BR112015001313A2 (pt) | 2012-07-24 | 2013-07-24 | composições de vacina |
Country Status (15)
Country | Link |
---|---|
US (1) | US20150265695A1 (pt) |
EP (1) | EP2877207A1 (pt) |
JP (1) | JP2015524422A (pt) |
KR (1) | KR20150036593A (pt) |
CN (1) | CN104812408A (pt) |
AU (1) | AU2013295016A1 (pt) |
BR (1) | BR112015001313A2 (pt) |
CA (1) | CA2878599A1 (pt) |
GT (1) | GT201500005A (pt) |
HK (1) | HK1212905A1 (pt) |
MX (1) | MX2015000446A (pt) |
PE (1) | PE20150356A1 (pt) |
PH (1) | PH12014502875A1 (pt) |
SG (1) | SG11201500439RA (pt) |
WO (1) | WO2014016362A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ630869A (en) | 2013-03-15 | 2017-11-24 | Us Gov Health & Human Services | Compositions and methods for dengue virus chimeric constructs in vaccines |
US9861692B2 (en) | 2013-06-21 | 2018-01-09 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
CN106999564A (zh) | 2014-09-02 | 2017-08-01 | 赛诺菲巴斯德有限公司 | 针对登革热病毒疾病的疫苗组合物 |
US10098943B2 (en) * | 2014-09-11 | 2018-10-16 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
BR112017013270A2 (pt) * | 2014-12-22 | 2018-03-06 | Merck Sharp & Dohme | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. |
US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
US10105434B2 (en) | 2015-08-03 | 2018-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Immune enhancing recombinant dengue protein |
EP3355915B1 (en) * | 2015-09-29 | 2023-11-01 | Boehringer Ingelheim Animal Health USA Inc. | Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof |
US11531029B2 (en) | 2017-05-08 | 2022-12-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
SG11202002933TA (en) | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
EP3730620A4 (en) | 2017-12-21 | 2022-01-05 | Green Biomed, Inc. | CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION |
US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
ES2908304T3 (es) | 2018-09-05 | 2022-04-28 | Takeda Vaccines Inc | Dosis unitaria de vacuna contra el dengue y administración de la misma |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
PT1625852E (pt) | 1997-02-28 | 2010-08-27 | Acambis Inc | Vacinas quiméricas de flavivírus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
CA2368790A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
CA2365728A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
JP2002540170A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱2型ウイルスワクチン |
AU4040400A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
WO2001009309A2 (en) * | 1999-08-02 | 2001-02-08 | American Home Products Corporation | RESCUE OF MUMPS VIRUS FROM cDNA |
DK2278012T3 (en) | 2000-02-16 | 2015-12-07 | Us Government | Immunogenic dengue 2 virus chimeras |
ES2315221T3 (es) | 2000-05-30 | 2009-04-01 | Mahidol University | Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea. |
AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
WO2002095007A2 (en) | 2001-05-23 | 2002-11-28 | Dendreon San Diego Llc | Conjugates activated by cell surface proteases and therapeutic uses thereof |
EP1401859B1 (en) | 2001-06-01 | 2013-08-07 | Sanofi Pasteur Biologics Co. | Chimeric flavivirus vectors |
WO2003010197A2 (en) | 2001-07-25 | 2003-02-06 | Genset S.A. | Gmg-1 polynucleotides and polypeptides and uses thereof |
WO2003092592A2 (en) * | 2002-05-03 | 2003-11-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
US8071107B2 (en) * | 2003-09-17 | 2011-12-06 | Duke University | Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins |
BRPI0613328A2 (pt) | 2005-06-17 | 2011-01-04 | Sanofi Pasteur | cepa do vìrus da dengue-1 vivo atenuado, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada e fragmento de poliproteìna |
CA2611954C (en) * | 2005-06-17 | 2014-01-28 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
CA2618783A1 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
CA2676775A1 (en) * | 2007-01-31 | 2008-09-25 | Sanofi Pasteur Biologics Co. | Flavivirus vaccine vector against influenza virus |
US8715689B2 (en) * | 2008-04-30 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric west nile/dengue viruses |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
EA201290072A1 (ru) * | 2009-07-29 | 2012-12-28 | Бернд Хельмут Адам Рем | Полимерные частицы и их применение |
US8900596B2 (en) * | 2009-11-18 | 2014-12-02 | The Board Of Regents Of The University Of Texas System | Physicochemical (PCP) based consensus sequences and uses thereof |
GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
CN102906266A (zh) * | 2010-05-21 | 2013-01-30 | 高等教育联邦系统-匹兹堡大学 | 登革病毒通用序列及其使用方法 |
WO2012051491A1 (en) * | 2010-10-14 | 2012-04-19 | The United States Of America, As Represented By The Secretary National Institutes Of Health | Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting |
SG10201912291YA (en) * | 2012-07-24 | 2020-02-27 | Sanofi Pasteur | Vaccine compositions |
-
2013
- 2013-07-24 AU AU2013295016A patent/AU2013295016A1/en not_active Abandoned
- 2013-07-24 KR KR20157003822A patent/KR20150036593A/ko not_active Application Discontinuation
- 2013-07-24 MX MX2015000446A patent/MX2015000446A/es unknown
- 2013-07-24 SG SG11201500439RA patent/SG11201500439RA/en unknown
- 2013-07-24 WO PCT/EP2013/065669 patent/WO2014016362A1/en active Application Filing
- 2013-07-24 JP JP2015523550A patent/JP2015524422A/ja active Pending
- 2013-07-24 CN CN201380049741.2A patent/CN104812408A/zh active Pending
- 2013-07-24 US US14/416,492 patent/US20150265695A1/en not_active Abandoned
- 2013-07-24 CA CA2878599A patent/CA2878599A1/en not_active Abandoned
- 2013-07-24 BR BR112015001313A patent/BR112015001313A2/pt not_active IP Right Cessation
- 2013-07-24 PE PE2015000070A patent/PE20150356A1/es not_active Application Discontinuation
- 2013-07-24 EP EP13740025.5A patent/EP2877207A1/en not_active Withdrawn
-
2014
- 2014-12-23 PH PH12014502875A patent/PH12014502875A1/en unknown
-
2015
- 2015-01-12 GT GT201500005A patent/GT201500005A/es unknown
-
2016
- 2016-01-28 HK HK16100914.5A patent/HK1212905A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12014502875A1 (en) | 2015-02-23 |
WO2014016362A1 (en) | 2014-01-30 |
KR20150036593A (ko) | 2015-04-07 |
US20150265695A1 (en) | 2015-09-24 |
HK1212905A1 (zh) | 2016-06-24 |
CA2878599A1 (en) | 2014-01-30 |
EP2877207A1 (en) | 2015-06-03 |
AU2013295016A1 (en) | 2015-01-29 |
GT201500005A (es) | 2015-10-13 |
JP2015524422A (ja) | 2015-08-24 |
SG11201500439RA (en) | 2015-02-27 |
PE20150356A1 (es) | 2015-03-20 |
CN104812408A (zh) | 2015-07-29 |
MX2015000446A (es) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015001313A2 (pt) | composições de vacina | |
BR112015014477A2 (pt) | composições para limpeza pessoal contendo aminoácido de zinco/haleto de trimetilglicina | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
CR20110509A (es) | Composicion farmaceutica | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BR112014006220A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
CO6290682A2 (es) | Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c. | |
BR112014016649A2 (pt) | composições para tratamento dos cabelos | |
BR112013022094A2 (pt) | composições e métodos para o tratamento não cirúrgico da ptose | |
UY32455A (es) | Derivados de aminotetralina, composiciones farmacéuticas que la contienen, y sus usos en terapia | |
MX2021004211A (es) | Composiciones vacuna. | |
BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos | |
BR112014014789A2 (pt) | composição | |
BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
BR112014009376A2 (pt) | composições | |
BR112013026661A2 (pt) | método de entrega de vacina | |
BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
BR112014032759A2 (pt) | composições lipídicas de racecadotril | |
BR112013000779A2 (pt) | composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial | |
BR112015006464A2 (pt) | composição farmacêutica compreendendo rebamipida | |
BR112013027369A2 (pt) | composições e métodos | |
BR112014008190A2 (pt) | composições para realce da saúde da unha | |
BR112015002979B8 (pt) | Forma cristalina, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |